489 results on '"Banks, Matthew L."'
Search Results
152. Effects of Extended Cocaine Access and Cocaine Withdrawal on Choice Between Cocaine and Food in Rhesus Monkeys
- Author
-
Banks, Matthew L, primary and Negus, S Stevens, additional
- Published
- 2009
- Full Text
- View/download PDF
153. Effects of extended access and withdrawal on the reinforcing strength of cocaine using a cocaine vs. food concurrent‐choice procedure in rhesus monkeys
- Author
-
Banks, Matthew L, primary and Negus, S Stevens, additional
- Published
- 2009
- Full Text
- View/download PDF
154. Selective but Slight Enhancement of Delta Agonist‐Induced Antinociception by Repeated Morphine in Rhesus Monkeys
- Author
-
Negus, S. Stevens, primary, Banks, Matthew L., additional, Schrode, Katrina, additional, Morrissey, Ember, additional, and Rice, Kenner C., additional
- Published
- 2009
- Full Text
- View/download PDF
155. Effects of Histamine H3 Receptor Activation on the Behavioral-Stimulant Effects of Methamphetamine and Cocaine in Mice and Squirrel Monkeys
- Author
-
Banks, Matthew L., primary, Manvich, Daniel F., additional, Bauzo, Rayna M., additional, and Howell, Leonard L., additional
- Published
- 2009
- Full Text
- View/download PDF
156. Differential effects of histamine‐3 receptor activation on the behavioral‐stimulant effects of methamphetamine and cocaine in mice and squirrel monkeys
- Author
-
Banks, Matthew L, primary, Manvich, Daniel F, additional, Bauzo, Rayna M, additional, and Howell, Leonard L, additional
- Published
- 2008
- Full Text
- View/download PDF
157. Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys
- Author
-
Banks, Matthew L., primary, Sprague, Jon E., additional, Czoty, Paul W., additional, and Nader, Michael A., additional
- Published
- 2007
- Full Text
- View/download PDF
158. Ambient Temperature Effects on 3,4-Methylenedioxymethamphetamine-Induced Thermodysregulation and Pharmacokinetics in Male Monkeys
- Author
-
Banks, Matthew L., primary, Sprague, Jon E., additional, Kisor, David F., additional, Czoty, Paul W., additional, Nichols, David E., additional, and Nader, Michael A., additional
- Published
- 2007
- Full Text
- View/download PDF
159. Effects of Cocaine and MDMA Self-Administration on Serotonin Transporter Availability in Monkeys
- Author
-
Banks, Matthew L, primary, Czoty, Paul W, additional, Gage, H Donald, additional, Bounds, Michael C, additional, Garg, Pradeep K, additional, Garg, Sudha, additional, and Nader, Michael A, additional
- Published
- 2007
- Full Text
- View/download PDF
160. Hypothyroidism alters striatal dopamine release mediated by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
- Author
-
Peterson, Andrea L., primary, Gilman, Tracy L., additional, Banks, Matthew L., additional, and Sprague, Jon E., additional
- Published
- 2006
- Full Text
- View/download PDF
161. Voltammetric assessment of dopamine clearance in the absence of the dopamine transporter: no contribution of other transporters in core or shell of nucleus accumbens
- Author
-
Mateo, Yolanda, primary, Budygin, Evgeny A., additional, John, Carrie E., additional, Banks, Matthew L., additional, and Jones, Sara R., additional
- Published
- 2004
- Full Text
- View/download PDF
162. Dantrolene Use in 3,4-Methylenedioxymethamphetamine (“Ecstasy”)–Mediated Hyperthermia
- Author
-
Rusyniak, Daniel E., primary, Banks, Matthew L., additional, Mills, Edward M., additional, and Sprague, Jon E., additional
- Published
- 2004
- Full Text
- View/download PDF
163. Hypothalamic-Pituitary-Thyroid Axis and Sympathetic Nervous System Involvement in Hyperthermia Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy)
- Author
-
Sprague, Jon E., primary, Banks, Matthew L., additional, Cook, Valerie J., additional, and Mills, Edward M., additional
- Published
- 2003
- Full Text
- View/download PDF
164. Synthetic cathinones ("bath salts").
- Author
-
Banks, Matthew L, Worst, Travis J, Rusyniak, Daniel E, and Sprague, Jon E
- Subjects
- *
SUBSTANCE abuse treatment , *SUBSTANCE abuse diagnosis , *SYNTHETIC cathinone , *CENTRAL nervous system stimulants , *DESIGNER drugs , *PSYCHIATRIC drugs , *ALKALOIDS , *RESEARCH funding - Abstract
Background: Synthetic cathinones are popularly referred to in the media as "bath salts." Through the direct and indirect activation of the sympathetic nervous system, smoking, snorting, or injecting synthetic cathinones can result in tachycardia, hypertension, hyperthermia, myocardial infarction, and death.Objective: The chemical structures and names of bath salts identified by the Ohio Attorney General's Bureau of Criminal Investigation are presented. Based on their common pharmacophores, we review the history, pharmacology, toxicology, detection methods, and clinical implications of synthetic cathinones. Through the integration of this information, the pharmacological basis for the management of patients using synthetic cathinones is presented.Discussion: Synthetic cathinones activate central serotonergic and dopaminergic systems contributing to acute psychosis and the peripheral activation of the sympathetic nervous system. The overstimulation of the sympathetic nervous system contributes to the many toxicities reported with bath salt use. The pharmacological basis for managing these patients is targeted at attenuating the activation of these systems.Conclusions: Treatment of patients presenting after using bath salts should be focused on reducing agitation and psychosis and supporting renal perfusion. The majority of successfully treated synthetic cathinones cases have used benzodiazepines and antipsychotics along with general supportive care. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
165. Pain-Related Depression of the Mesolimbic Dopamine System in Rats: Expression, Blockade by Analgesics, and Role of Endogenous κ-opioids.
- Author
-
Leitl, Michael D, Onvani, Sara, Bowers, M Scott, Cheng, Kejun, Rice, Kenner C, Carlezon, William A, Banks, Matthew L, and Negus, S Stevens
- Subjects
DOPAMINE ,MENTAL depression ,NUCLEUS accumbens ,BRAIN stimulation ,DYNORPHINS ,NEUROPSYCHOPHARMACOLOGY - Abstract
Pain is often associated with depression of behavior and mood, and relief of pain-related depression is a common goal of treatment. This study tested the hypothesis that pain-related behavioral depression is mediated by activation of endogenous κ-opioid systems and subsequent depression of mesolimbic dopamine release. Adult male Sprague-Dawley rats were implanted with electrodes targeting the medial forebrain bundle (for behavior studies of intracranial self-stimulation (ICSS)) or with cannulae for microdialysis measures of nucleus accumbens dopamine (NAc DA). Changes in ICSS and NAc DA were examined after treatment with a visceral noxious stimulus (intraperitoneal injection of dilute lactic acid) or an exogenous κ-agonist (U69593). Additional studies examined the sensitivity of acid and U69593 effects to blockade by two analgesics (the nonsteroidal antiinflammatory drug ketoprofen and the μ-opioid agonist morphine) or by the κ-antagonist norbinaltorphimine (norBNI). The effects of acid were also examined on mRNA expression for prodynorphin (PDYN) and κ-opioid receptors (KORs) in mesocorticolimbic brain regions. Both acid and U69593 depressed ICSS and extracellular levels of NAc DA. Pain-related acid effects were blocked by ketoprofen and morphine but not by norBNI. The U69593 effects were blocked by norBNI but not by ketoprofen, and were only attenuated by morphine. Acid did not significantly alter PDYN or KOR in NAc, but it produced a delayed increase in PDYN in prefrontal cortex. These results support a key role for the mesolimbic DA system, but a more nuanced role for endogenous κ-opioid systems, in mediating acute pain-related behavioral depression in rats. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
166. Corrigendum to “Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys” [Drug Alcohol Depend. 131 (2013) 204–213]
- Author
-
Banks, Matthew L., Blough, Bruce E., and Negus, S. Stevens
- Published
- 2013
- Full Text
- View/download PDF
167. Adding dopamine to the complexity of sex differences in opioid reinforcement
- Author
-
Robinson, Hannah L. and Banks, Matthew L.
- Published
- 2021
- Full Text
- View/download PDF
168. Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys.
- Author
-
Banks, Matthew L., Blough, Bruce E., and Negus, S. Stevens
- Subjects
- *
APPETITE depressants , *COCAINE abuse , *PRODRUGS , *FOOD , *RHESUS monkeys , *AMPHETAMINE abuse , *TREATMENT duration , *INTRAVENOUS therapy - Abstract
Abstract: Background: The clinical utility of monoamine releasers such as phenmetrazine or d-amphetamine as candidate agonist medications for cocaine dependence is hindered by their high abuse liability. Phendimetrazine is a clinically available schedule III anorectic that functions as a prodrug for phenmetrazine and thus may have lower abuse liability. This study determined the effects of continuous 14-day treatment with phendimetrazine on cocaine vs. food choice in rhesus monkeys (N =4). Methods: Responding was maintained under a concurrent schedule of food delivery (1-g pellets, fixed-ratio 100 schedule) and cocaine injections (0–0.1mg/kg/injection, fixed-ratio 10 schedule). Cocaine choice dose–effect curves were determined daily before and during 14-day periods of continuous intravenous treatment with saline or (+)-phendimetrazine (0.32–1.0mg/kg/h). Effects of 14-day treatment with (+)-phenmetrazine (0.1–0.32mg/kg/h; N =5) and d-amphetamine (0.032–0.1mg/kg/h; N =6) were also examined for comparison. Results: During saline treatment, food was primarily chosen during availability of low cocaine doses (0, 0.0032, and 0.01mg/kg/injection), and cocaine was primarily chosen during availability of higher cocaine doses (0.032 and 0.1mg/kg/injection). Phendimetrazine initially decreased overall responding without significantly altering cocaine choice. Over the course of 14 days, tolerance developed to rate decreasing effects, and phendimetrazine dose-dependently decreased cocaine choice (significant at 0.032mg/kg/injection cocaine). Phenmetrazine and d-amphetamine produced qualitatively similar effects. Conclusions: These results demonstrate that phendimetrazine can produce significant, though modest, reductions in cocaine choice in rhesus monkeys. Phendimetrazine may be especially suitable as a candidate medication for human studies because of its schedule III clinical availability. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
169. Role of phenmetrazine as an active metabolite of phendimetrazine: Evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys
- Author
-
Banks, Matthew L., Blough, Bruce E., Fennell, Timothy R., Snyder, Rodney W., and Negus, S. Stevens
- Subjects
- *
PHENETHYLAMINES , *DRUG discrimination (Pharmacology) , *PHARMACOKINETICS , *RHESUS monkeys , *LABORATORY monkeys , *AMPHETAMINES , *DOPAMINE , *NORADRENALINE - Abstract
Abstract: Background: Monoamine releasers such as d-amphetamine that selectively promote release of dopamine/norepinephrine versus serotonin are one class of candidate medications for treating cocaine dependence; however, their clinical utility is limited by undesirable effects such as abuse liability. Clinical utility of these compounds may be increased by development of prodrugs to reduce abuse potential by slowing onset of drug effects. This study examined the behavioral and pharmacokinetic profile of the Schedule III compound phendimetrazine, which may serve as a prodrug for the N-demethylated metabolite and potent dopamine/norepinephrine releaser phenmetrazine. Methods: Monkeys (n =5) were trained in a two-key food-reinforced discrimination procedure to discriminate cocaine (0.32mg/kg, IM) from saline, and the potency and time course of cocaine-like discriminative stimulus effects were determined for (+)-phenmetrazine, (−)-phenmetrazine, (+)-phendimetrazine, (−)-phendimetrazine, and (±)-phendimetrazine. Parallel pharmacokinetic studies in the same monkeys examined plasma phenmetrazine and phendimetrazine levels for correlation with cocaine-like discriminative stimulus effects. Results: Both isomers of phenmetrazine, and the racemate and both isomers of phendimetrazine, produced dose- and time-dependent substitution for the discriminative stimulus effects of cocaine, with greater potency residing in the (+) isomers. In general, plasma phenmetrazine levels increased to similar levels after administration of behaviorally active doses of either phenmetrazine or phendimetrazine. Conclusions: These results support the hypothesis that phenmetrazine is an active metabolite that contributes to the effects of phendimetrazine. However, behavioral effects of phendimetrazine had a more rapid onset than would have been predicted by phenmetrazine levels alone, suggesting that other mechanisms may also contribute. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
170. Interaction Between Behavioral and Pharmacological Treatment Strategies to Decrease Cocaine Choice in Rhesus Monkeys.
- Author
-
Banks, Matthew L, Blough, Bruce E, and Stevens Negus, S
- Subjects
- *
COCAINE abuse treatment , *BEHAVIOR therapy , *DRUG therapy , *INTRAVENOUS catheterization , *CHEMICAL agonists , *RHESUS monkeys - Abstract
Behavioral and pharmacotherapeutic approaches constitute two prominent strategies for treating cocaine dependence. This study investigated interactions between behavioral and pharmacological strategies in a preclinical model of cocaine vs food choice. Six rhesus monkeys, implanted with a chronic indwelling double-lumen venous catheter, initially responded under a concurrent schedule of food delivery (1-g pellets, fixed-ratio (FR) 100 schedule) and cocaine injections (0-0.1 mg/kg/injection, FR 10 schedule) during continuous 7-day treatment periods with saline or the agonist medication phenmetrazine (0.032-0.1 mg/kg/h). Subsequently, the FR response requirement for cocaine or food was varied (food, FR 100; cocaine, FR 1-100; cocaine, FR 10; food, FR 10-300), and effects of phenmetrazine on cocaine vs food choice were redetermined. Decreases in the cocaine FR or increases in the food FR resulted in leftward shifts in the cocaine choice dose-effect curve, whereas increases in the cocaine FR or decreases in the food FR resulted in rightward shifts in the cocaine choice dose-effect curve. The efficacy of phenmetrazine to decrease cocaine choice varied systematically as a function of the prevailing response requirements, such that phenmetrazine efficacy was greatest when cocaine choice was maintained by relatively low unit cocaine doses. These results suggest that efficacy of pharmacotherapies to modulate cocaine use can be influenced by behavioral contingencies of cocaine availability. Agonist medications may be most effective under contingencies that engender choice of relatively low cocaine doses. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
171. Effects of Extended Cocaine Access and Cocaine Withdrawal on Choice Between Cocaine and Food in Rhesus Monkeys.
- Author
-
Banks, Matthew L. and Negus, S. Stevens
- Subjects
- *
DRUG abuse , *COCAINE , *LOCAL anesthetics , *PSYCHIATRIC drugs , *OPIOIDS - Abstract
Chronic drug use may lead to sufficient drug intake to produce dependence and the emergence of abstinence signs during withdrawal. Although withdrawal can increase the reinforcing effects of some drugs (eg opioids), the impact of withdrawal on the reinforcing effects of stimulants like cocaine is less clear. This study used a novel cocaine vs food choice procedure to examine the relative reinforcing strength of cocaine before, during, and after exposure to graded levels of extended cocaine access. Responding in four rhesus monkeys was maintained by cocaine (0–0.1 mg/kg/injection) and food delivery under a concurrent-choice schedule during daily 2-h sessions. Under baseline conditions, cocaine maintained a dose-dependent increase in cocaine choice. Subsequently, subjects were exposed to and withdrawn from periods of extended cocaine access, which was accomplished by implementing daily 21-h supplemental sessions of cocaine self-administration in addition to daily choice sessions. During supplemental sessions, cocaine (0.1 mg/kg/injection) was available under a fixed-ratio 10/time-out X schedule, and the duration of the time-out was varied from 30 to 7.5 min. Cocaine intake increased 10-fold to >11 mg/kg/day during exposure to supplemental sessions with the shortest post-injection time-out. However, parameters of cocaine choice were not significantly affected either during or after extended cocaine access. These results do not support the hypothesis that cocaine withdrawal increases the reinforcing strength of cocaine. This differs from results with the opioid agonist heroin and suggests that withdrawal may have different functions in the maintenance of opioid and stimulant abuse. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
172. Effects of Histamine H3 Receptor Activation on the Behavioral-Stimulant Effects of Methamphetamine and Cocaine in Mice and Squirrel Monkeys.
- Author
-
Banks, Matthew L., Manvich, Daniel F., Bauzo, Rayna M., and Howell, Leonard L.
- Subjects
- *
COCAINE , *METHAMPHETAMINE , *STIMULANTS , *HISTAMINE receptors , *LABORATORY mice , *LABORATORY monkeys - Abstract
Background: Cocaine and methamphetamine (METH) are two commonly abused drugs that have behavioral-stimulant properties. These stimulant effects are partially mediated by the dopaminergic system. Recent evidence has suggested that the histamine H3 receptor (H3R) may modulate the release of dopamine induced by METH. The aim of the present study was to examine the role of H3R in the behavioral-stimulant effects of cocaine and METH in mice and monkeys. Methods: Nonhabituated, experimentally naïve mice (n = 5–6) were pretreated with the H3R agonist imetit 30 min before METH or cocaine, and activity was measured for 90 min. The behavioral-stimulant effects of METH and cocaine were also studied in squirrel monkeys (n = 3) under a fixed-interval schedule of stimulus termination. Monkeys were pretreated with imetit 30 min before the peak behavioral-stimulant doses of METH or cocaine derived from individual subjects. Results: Pretreatment with imetit did not affect basal activity in mice. Imetit significantly attenuated the behavioral-stimulant effects of METH, but not cocaine. In monkeys, no dose of imetit tested significantly altered the behavioral-stimulant effects of METH or cocaine. Conclusion: These results suggest a role of H3R in the behavioral-stimulant effects of METH, but not cocaine, in mice and no role in monkeys. Copyright © 2009 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
173. Effects of Cocaine and MDMA Self-Administration on Serotonin Transporter Availability in Monkeys.
- Author
-
Banks, Matthew L., Czoty, Paul W., Gage, H. Donald, Bounds, Michael C., Garg, Pradeep K., Garg, Sudha, and Nader, Michael A.
- Subjects
- *
COCAINE , *SEROTONIN , *DOPAMINE , *POSITRON emission tomography , *RHESUS monkeys , *CAUDATE nucleus - Abstract
Although serotonin (5-HT) can interact with dopamine (DA) systems to modulate the subjective and reinforcing effects of psychostimulants such as cocaine and 3,4-methyldioxymethamphetamine (MDMA, ecstasy), the long-term effects of exposure to psychostimulants on brain 5-HT systems are not well characterized. The present study assessed 5-HT transporter (SERT) availability using positron emission tomography (PET) in rhesus monkeys with the SERT-specific radioligand [11C]3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB). SERT availability was assessed in regions of interest including the caudate nucleus, putamen, anterior cingulate cortex, and cerebellum. [11C]DASB distribution volume ratios (DVRs) were calculated using the cerebellum as the reference region. DVRs were calculated in control monkeys and in cocaine or MDMA self-administering monkeys approximately 24 h after the last self-administration (SA) session. SERT availability did not differ between monkeys with a history of MDMA SA and control monkeys in any region examined. In contrast, monkeys with a history of cocaine SA showed significantly higher levels of SERT availability in the caudate nucleus and putamen compared to control subjects. These results suggest that chronic SA of cocaine, but not MDMA, leads to alterations in serotonergic function in brain areas relevant to drug abuse. The higher level of SERT availability in cocaine-experienced monkeys may lead to a reduced inhibitory tone of 5-HT on the DA system, which may explain, in part, differences in the abuse liability between cocaine and MDMA.Neuropsychopharmacology (2008) 33, 219–225; doi:10.1038/sj.npp.1301420; published online 18 April 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
174. Logical fallacies and misinterpretations that hinder progress in translational addiction neuroscience.
- Author
-
Strickland, Justin C., Stoops, William W., Banks, Matthew L., and Gipson, Cassandra D.
- Subjects
- *
LOGICAL fallacies , *ADDICTIONS , *SUBSTANCE abuse , *HUMAN behavior models , *NEUROSCIENCES , *COCAINE-induced disorders - Abstract
Substance use disorders (SUDs) are heterogeneous and complex, making the development of translationally predictive rodent and nonhuman primate models to uncover their neurobehavioral underpinnings difficult. Neuroscience‐focused outcomes have become highly prevalent, and with this, the notion that SUDs are disorders of the brain embraced as a dominant theoretical orientation to understand SUD etiology and treatment. These efforts, however, have led to few efficacious pharmacotherapies, and in some cases (as with cocaine or methamphetamine), no pharmacotherapies have translated from preclinical models for clinical use. In this theoretical commentary, we first describe the development of animal models of substance use behaviors from a historical perspective. We then define and discuss three logical fallacies including 1) circular explanation, 2) affirming the consequent, and 3) reification that can apply to developed models. We then provide three case examples in which conceptual or logical issues exist in common methods (i.e., behavioral economic demand, escalation, and reinstatement). Alternative strategies to refocus behavioral models are suggested for the field to better bridge the translational divide between animal models, the clinical condition of SUDs, and current and future regulatory pathways for intervention development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
175. Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications
- Author
-
Banks, Matthew L., Townsend, E. Andrew, and Negus, S. Stevens
- Published
- 2019
- Full Text
- View/download PDF
176. Impaired cognitive behavioral flexibility following methamphetamine or high caloric diet consumption: a common 5-HT2Cmechanism?
- Author
-
Banks, Matthew L.
- Published
- 2019
- Full Text
- View/download PDF
177. Effects of 21-day d-amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys.
- Author
-
Hutsell, Blake A., Negus, S. Stevens, and Banks, Matthew L.
- Subjects
- *
COCAINE abuse treatment , *RISPERIDONE , *AMPHETAMINES , *DRUG administration , *TREATMENT effectiveness , *RHESUS monkeys , *THERAPEUTICS , *ANIMAL experimentation , *CLINICAL trials , *COCAINE , *DECISION making , *DOPAMINE antagonists , *DOSE-effect relationship in pharmacology , *FOOD , *DOPAMINE uptake inhibitors , *PRIMATES , *RESEARCH funding , *SELF medication , *CENTRAL nervous system stimulants , *DEXTROAMPHETAMINE , *PHARMACODYNAMICS - Abstract
Background: Clinical trial data suggest amphetamine treatment is most efficacious in moderate to high frequency cocaine users. However, preclinical studies have examined amphetamine treatment effects under relatively limited cocaine access conditions with low to moderate cocaine intakes. This study determined d-amphetamine treatment effects on cocaine self-administration in rhesus monkeys under cocaine access conditions allowing for high daily cocaine intake. For comparison and as a negative control, treatment effects with the antipsychotic risperidone were also examined.Methods: Continuous 21-day treatments with ramping doses of d-amphetamine (days 1-7: 0.032mg/kg/h; days 8-21: 0.1mg/kg/h, i.v.) or risperidone (days 1-7: 0.001mg/kg/h; days 8-14: 0.0032mg/kg/h; days 15-21: 0.0056mg/kg/h, i.v.) were administered to rhesus monkeys (n=4) with daily access to two types of cocaine self-administration sessions: (1) a 2-h 'choice' session with concurrent availability of 1-g food pellets and intravenous cocaine injections (0-0.1mg/kg per injection) and (2) a 20-h 'extended-access' session with 0.1mg/kg per injection cocaine availability.Results: Total daily cocaine intake increased >6-fold during extended cocaine access. d-Amphetamine significantly decreased total cocaine intake, but not cocaine vs food choice. In contrast, risperidone did not significantly alter either total cocaine intake or cocaine vs. food choice.Conclusions: These results confirm and extend previous results supporting treatment effectiveness for monoamine releasers, but not dopamine antagonists, to reduce cocaine self-administration. Moreover, these results suggest amphetamine treatment efficacy to decrease preclinical cocaine vs. food choice may depend upon cocaine access conditions. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
178. Effects of environmental manipulations on cocaine-vs-social choice in male and female rats.
- Author
-
Marcus, Madison M., Negus, S. Stevens, and Banks, Matthew L.
- Subjects
- *
COCAINE-induced disorders , *REINFORCEMENT (Psychology) , *SOCIAL interaction , *ENVIRONMENTAL literacy , *INTRAVENOUS therapy , *RATS - Abstract
Cocaine use disorder occurs in an environment where cocaine and other nondrug commodities are concurrently available. Preclinical drug-vs-nondrug choice procedures are one simplified method of modeling this complex clinical environment. The present study established a discrete-trial cocaine-vs-social interaction choice procedure in male and female rats and determined sensitivity of choice behavior to manipulations of reinforcer magnitude and non-contingent "sample" reinforcer presentation. Rats could make up to nine discrete choices between an intravenous cocaine infusion (0.1–1.0 mg/kg/inf) and social interaction with a same-sex social "Partner" rat. Cocaine infusions were available under a progressive-ratio (PR) schedule of reinforcement, and social interaction was available under a fixed-ratio (FR) 3 schedule. Social interaction was chosen over no or small cocaine doses (saline, 0.01 mg/kg/inf) and behavior was reallocated away from social and towards cocaine at larger cocaine doses (1.0 mg/kg/inf). Manipulating social interaction time as one method to alter social reinforcer magnitude did not significantly alter cocaine-vs-social choice. Removing the non-contingent reinforcer presentations before the discrete choice trials also failed to affect cocaine-vs-social choice, suggesting the time interval was sufficient to minimize any potential influence of the non-contingent cocaine infusions on subsequent choice behavior. Overall, the present results were consistent with previous drug-vs-social choice studies and extend our knowledge of environmental factors impacting drug-vs-social choice. Future studies determining the pharmacological sensitivity of cocaine-vs-social choice will be important in expanding the preclinical utility of these procedures for candidate medication drug development. • Cocaine was chosen over social interaction in both female and male rats. • Manipulation of social access time failed to alter cocaine-vs-social choice. • Removing non-contingent reinforcer presentations did not attenuate cocaine choice. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
179. A generalized matching law analysis of cocaine vs. food choice in rhesus monkeys: effects of candidate 'agonist-based' medications on sensitivity to reinforcement.
- Author
-
Hutsell, Blake A, Negus, S Stevens, and Banks, Matthew L
- Abstract
Background: We have previously demonstrated reductions in cocaine choice produced by either continuous 14-day phendimetrazine and d-amphetamine treatment or removing cocaine availability under a cocaine vs. food choice procedure in rhesus monkeys. The aim of the present investigation was to apply the concatenated generalized matching law (GML) to cocaine vs. food choice dose-effect functions incorporating sensitivity to both the relative magnitude and price of each reinforcer. Our goal was to determine potential behavioral mechanisms underlying pharmacological treatment efficacy to decrease cocaine choice.Methods: A multi-model comparison approach was used to characterize dose- and time-course effects of both pharmacological and environmental manipulations on sensitivity to reinforcement.Results: GML models provided an excellent fit of the cocaine choice dose-effect functions in individual monkeys. Reductions in cocaine choice by both pharmacological and environmental manipulations were principally produced by systematic decreases in sensitivity to reinforcer price and non-systematic changes in sensitivity to reinforcer magnitude.Conclusions: The modeling approach used provides a theoretical link between the experimental analysis of choice and pharmacological treatments being evaluated as candidate 'agonist-based' medications for cocaine addiction. The analysis suggests that monoamine releaser treatment efficacy to decrease cocaine choice was mediated by selectively increasing the relative price of cocaine. Overall, the net behavioral effect of these pharmacological treatments was to increase substitutability of food pellets, a nondrug reinforcer, for cocaine. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
180. Lack of effect of the nociceptin opioid peptide agonist Ro 64-6198 on pain-depressed behavior and heroin choice in rats.
- Author
-
Moerke, Megan Jo, Negus, S. Stevens, and Banks, Matthew L.
- Subjects
- *
PEPTIDES , *NOCICEPTIN , *OPIOID abuse , *BRAIN stimulation , *PEPTIDE receptors , *DRUG-seeking behavior , *SUBSTANCE abuse , *PAIN , *ANIMAL experimentation , *HYDROCARBONS , *IMIDAZOLES , *RATS , *DOSE-effect relationship in pharmacology , *RESEARCH funding , *OPIOID peptides , *HEROIN , *PHARMACODYNAMICS - Abstract
Rationale and Objective: One objective of the National Institutes of Health Helping to End Addiction Long-term (HEAL) initiative is to accelerate research on safer and more effective medications for both pain and opioid use disorder. Ligands that activate the nociceptin opioid peptide receptor (NOP) constitute one class of candidate drugs for both applications. The present preclinical study determined the effectiveness of the NOP agonist Ro 64-6198 to produce antinociception in a pain-depressed behavior procedure and attenuate opioid self-administration in a heroin-vs-food choice procedure.Methods: In Experiment 1, Adult Sprague-Dawley rats were equipped with microelectrodes and trained to respond for electrical brain stimulation in an intracranial self-stimulation (ICSS) procedure. The potency, time course, and receptor mechanism of effects produced by R0 64-6198 alone (0.32-3.2 mg/kg) on ICSS were examined, followed by evaluation of 0.32-1.0 mg/kg Ro 64-6198 effectiveness to block lactic acid-induced depression of ICSS. In Experiment 2, rats self-administered heroin under a heroin-vs-food choice procedure during a regimen of repeated, daily intraperitoneal administration of vehicle or Ro 64-6198 (1-3.2 mg/kg/day).Results: Ro 64-6198 produced dose- and time-dependent ICSS depression that was blocked by the selective NOP antagonist SB612111 but not by naltrexone. Ro 64-6198 failed to block acid-induced depression of ICSS. Repeated Ro 64-6198 pretreatment also failed to attenuate heroin-vs-food choice up to doses that significantly decreased operant behavior.Conclusions: These results do not support the utility of Ro 64-6198 as a stand-alone medication for either acute pain or opioid use disorder. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
181. Xylazine does not enhance fentanyl reinforcement in rats: A behavioral economic analysis.
- Author
-
St. Onge, Celsey M., Canfield, Jeremy R., Ortiz, Allison, Sprague, Jon E., and Banks, Matthew L.
- Subjects
- *
FENTANYL , *BEHAVIORAL assessment , *REINFORCEMENT (Psychology) , *XYLAZINE , *DRUG interactions - Abstract
The adulteration of illicit fentanyl with the alpha-2 agonist xylazine has been designated an emerging public health threat. The clinical rationale for combining fentanyl with xylazine is currently unclear, and the inability to study fentanyl/xylazine interactions in humans warrants the need for preclinical research. We studied fentanyl and xylazine pharmacodynamic and pharmacokinetic interactions in male and female rats using drug self-administration behavioral economic methods. Fentanyl, but not xylazine, functioned as a reinforcer under both fixed-ratio and progressive-ratio drug self-administration procedures. Xylazine combined with fentanyl at three fixed dose-proportion mixtures did not significantly alter fentanyl reinforcement as measured using behavioral economic analyses. Xylazine produced a proportion-dependent decrease in the behavioral economic Q 0 endpoint compared to fentanyl alone. However, xylazine did not significantly alter fentanyl self-administration at FR1. Fentanyl and xylazine co-administration did not result in changes to pharmacokinetic endpoints. The present results demonstrate that xylazine does not enhance the addictive effects of fentanyl or alter fentanyl plasma concentrations. The premise for why illicitly manufacture fentanyl has been adulterated with xylazine remains to be determined. [Display omitted] • Fentanyl, but not xylazine, functioned as a reinforcer. • Increasing proportions of xylazine did not alter fentanyl essential value. • Increasing proportions of xylazine decreased Q 0. • Xylazine did not alter fentanyl pharmacokinetic measures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
182. Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats.
- Author
-
Reiner, David J., Townsend, E. Andrew, Orihuel, Javier, Applebey, Sarah V., Claypool, Sarah M., Banks, Matthew L., Shaham, Yavin, and Negus, S. Stevens
- Subjects
- *
OPIOIDS , *FENTANYL , *RATS , *LACTIC acid , *OPIOID abuse , *VISCERAL pain , *INJECTIONS , *CHRONIC pain - Abstract
Rationale and objective: Pain-related factors increase the risk for opioid addiction, and pain may function as a negative reinforcer to increase opioid taking and seeking. However, experimental pain-related manipulations generally do not increase opioid self-administration in rodents. This discrepancy may reflect insufficient learning of pain-relief contingencies or confounding effects of pain-related behavioral impairments. Here, we determined if pairing noxious stimuli with opioid self-administration would promote pain-related reinstatement of opioid seeking or increase opioid choice over food. Methods: In Experiment 1, rats self-administered fentanyl in the presence or absence of repeated intraplantar capsaicin injections in distinct contexts to model context-specific exposure to cutaneous nociception. After capsaicin-free extinction in both contexts, we tested if capsaicin would reinstate fentanyl seeking. In Experiment 2, rats self-administered heroin after intraperitoneal (i.p.) lactic acid injections to model acute visceral inflammatory pain. After lactic acid-free extinction, we tested if lactic acid would reinstate heroin seeking. In Experiment 3, we tested if repeated i.p. lactic acid or intraplantar Complete Freund's Adjuvant (CFA; to model sustained inflammatory pain) would increase fentanyl choice over food. Results: In Experiments 1-2, neither capsaicin nor lactic acid reinstated opioid seeking after extinction, and lactic acid did not increase heroin-induced reinstatement. In Experiment 3, lactic acid and CFA decreased reinforcement rate without affecting fentanyl choice. Conclusions: Results extend the range of conditions across which pain-related manipulations fail to increase opioid seeking in rats and suggest that enhanced opioid-addiction risk in humans with chronic pain involves factors other than enhanced opioid reinforcement and relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
183. Comparison of three DREADD agonists acting on Gq-DREADDs in the ventral tegmental area to alter locomotor activity in tyrosine hydroxylase:Cre male and female rats.
- Author
-
Robinson, Hannah L., Nicholson, Katherine L., Shelton, Keith L., Hamilton, Peter J., and Banks, Matthew L.
- Subjects
- *
PSYCHOPHARMACOLOGY , *TYROSINE , *RATS , *BEHAVIORAL neuroscience , *SPRAGUE Dawley rats - Abstract
Despite the increasingly pervasive use of chemogenetic tools in preclinical neuroscience research, the in vivo pharmacology of DREADD agonists remains poorly understood. The pharmacological effects of any ligand acting at receptors, engineered or endogenous, are influenced by numerous factors including potency, time course, and receptor selectivity. Thus, rigorous comparison of the potency and time course of available DREADD ligands may provide an empirical foundation for ligand selection. Compare the behavioral pharmacology of three different DREADD ligands clozapine-N-oxide (CNO), compound 21 (C21), and deschloroclozapine (DCZ) in a locomotor activity assay in tyrosine hydroxylase:cre recombinase (TH:Cre) male and female rats. Locomotor activity in nine adult TH:Cre Sprague-Dawley rats (5 female, 4 male) was monitored for two hours following administration of d -amphetamine (vehicle, 0.1–3.2 mg/kg, IP), DCZ (vehicle, 0.32–320 µg/kg, IP), CNO (vehicle, 0.32–10 mg/kg), and C21 (vehicle, 0.1–3.2 mg/kg, IP). Behavioral sessions were conducted twice per week prior to and starting three weeks after bilateral intra-VTA hM3Dq DREADD virus injection. d -Amphetamine significantly increased locomotor activity pre- and post-DREADD virus injection. DCZ, CNO, and C21 did not alter locomotor activity pre-DREADD virus injection. There was no significant effect of DCZ, CNO, and C21 on locomotor activity post-DREADD virus injection; however, large individual differences in both behavioral response and receptor expression were observed. Large individual variability was observed in both DREADD agonist behavioral effects and receptor expression. These results suggest further basic research would facilitate the utility of these chemogenetic tools for behavioral neuroscience research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
184. The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.
- Author
-
Crowe, Molly S, Wilson, Catheryn D, Leishman, Emma, Prather, Paul L, Bradshaw, Heather B, Banks, Matthew L, and Kinsey, Steven G
- Subjects
- *
LIPASE inhibitors , *GABAPENTIN , *ANALGESIA , *ALLODYNIA , *PHARMACODYNAMICS - Abstract
Background and Purpose: Gabapentin is commonly prescribed for nerve pain but may also cause dizziness, sedation and gait disturbances. Similarly, inhibition of the endogenous cannabinoid enzyme monoacylglycerol lipase (MAGL) has antinociceptive and anti-inflammatory properties but also induces sedation in mice at high doses. To limit these side effects, the present study investigated the analgesic effects of coadministering a MAGL inhibitor with gabapentin.Experimental Approach: Mice subjected to the chronic constriction injury model of neuropathic pain were administered the MAGL inhibitor KML29 (1-40 mg·kg-1 , i.p.), gabapentin (1-50 mg·kg-1 , i.p.) or both compounds. Mice were tested for mechanical and cold allodynia. The function and expression of cannabinoid CB1 receptors in whole brain homogenates and lipid profile of spinal cords were assessed after repeated drug administration.Key Results: The combination of low-dose KML29:gabapentin additively attenuated mechanical allodynia and synergistically reduced cold allodynia. The CB1 antagonist, rimonabant, partially reversed the anti-allodynic effects of KML29:gabapentin in mechanical allodynia but not cold allodynia. The anti-allodynic effects of KML29:gabapentin did not undergo tolerance in mechanical allodynia after repeated administration but produced mild tolerance in cold allodynia. High dose KML29 alone reduced CB1 receptor expression and function, but KML29:gabapentin reduced the density of CB1 receptors but did not alter their function. KML29:gabapentin influenced additional signalling pathways (including fatty acids) other than the pathways activated by a higher dose of either drug alone.Conclusion and Implications: These data support the strategy of combining MAGL inhibition with a commonly prescribed analgesic as a therapeutic approach for attenuating neuropathic pain. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
185. Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.
- Author
-
Smith, Douglas A., Negus, S. Stevens, Poklis, Justin L., Blough, Bruce E., and Banks, Matthew L.
- Subjects
- *
COCAINE , *RHESUS monkeys , *CATHINONE , *MONOAMINE transporters , *DRUG abuse , *ANIMAL experimentation , *CONDITIONED response , *HETEROCYCLIC compounds , *INTRAMUSCULAR injections , *KETONES , *LEARNING , *DOPAMINE uptake inhibitors , *METHAMPHETAMINE , *PRIMATES , *REINFORCEMENT (Psychology) , *RESEARCH funding , *CENTRAL nervous system stimulants - Abstract
Synthetic cathinones are beta-ketone amphetamine analogs that have emerged as a heterogeneous class of abused compounds that function as either monoamine transporter substrates or inhibitors. Pre-clinical drug discrimination procedures are useful for interrogating structure-activity relationships of abuse-related drug effects; however, in vivo structure-activity relationship comparisons between synthetic cathinones with different mechanisms of action are lacking. The aim of the present study was to determine whether the cocaine-like discriminative stimulus effects of the monoamine transporter inhibitor alpha-pyrrolidinovalerophenone (alpha-PVP) and the monoamine transporter substrate methcathinone were differentially sensitive to 3,4-methylenedioxy and 4-methyl substitutions. Male rhesus monkeys (n = 4) were trained to discriminate intramuscular cocaine (0.32 mg/kg) from saline in a two-key food-reinforced discrimination procedure. Potency and timecourse of cocaine-like discriminative stimulus effects were determined for (±)-alpha-PVP, (±)-methcathinone and their 3,4-methylenedioxy or 4-methyl analogs. Alpha-PVP and methcathinone produced dose- and time-dependent cocaine-like effects. A 3,4-methylenedioxy addition to either alpha-PVP or methcathinone (methylone) did not alter the potency or efficacy to produce cocaine-like effects, but did prolong the time course. A 4-methyl addition to alpha-PVP (pyrovalerone) did not alter the potency or efficacy to produce cocaine-like effects, but did prolong the time course. In contrast, addition of a 4-methyl moiety to methcathinone (4MMC; mephedrone) significantly attenuated efficacy to produce cocaine-like effects. Overall, these results suggest different structural requirements for cocaine-like discriminative stimulus effects of monoamine transporter inhibitor and substrate synthetic cathinone analogs. Given that 4MMC is more hydrophobic than MDMC, these results suggest that hydrophobicity may be an important determinant for limiting monoamine transporter substrate abuse-related behavioral effects. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
186. Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats.
- Author
-
Hutsell, Blake A., Baumann, Michael H., Partilla, John S., Banks, Matthew L., Vekariya, Rakesh, Glennon, Richard A., and Negus, S. Stevens
- Subjects
- *
DRUG abuse , *NEUROCHEMISTRY , *CATHINONE , *STEREOISOMERS , *LABORATORY rats , *NEUROTRANSMITTERS - Abstract
Cathinone and many of its analogs produce behavioral effects by promoting transporter-mediated release of the monoamine neurotransmitters dopamine, norepinephrine and/or serotonin. Stereoselectivity is one determinant of neurochemical and behavioral effects of cathinone analogs. This study compared effectiveness of the S (−) and R (+) enantiomers of cathinone and 4-methylcathinone to produce in vitro monoamine release and in vivo abuse-related behavioral effects in rats. For neurochemical studies, drug effects were evaluated on monoamine release through dopamine, norepinephrine, and serotonin transporters (DAT, NET and SERT, respectively) in rat brain synaptosomes. For behavioral studies, drug effects were evaluated on responding for electrical brain stimulation in an intracranial self-stimulation (ICSS) procedure. The cathinone enantiomers differed in potency [ S (−)> R (+)], but both enantiomers were >50-fold selective at promoting monoamine release through DAT vs. SERT, and both enantiomers produced ICSS facilitation. The 4-methylcathinone enantiomers also differed in potency [ S (−)> R (+)]; however, in neurochemical studies, the decrease in potency from S (−) to R (+)4-methylcathinone was less for DAT than for SERT, and as a result, DAT vs. SERT selectivity was greater for R (+) than for S (−)4-methylcathinone (4.1- vs. 1.2-fold). Moreover, in behavioral studies, S (−)4-methylcathinone produced only ICSS depression, whereas R (+)4-methylcathinone produced ICSS facilitation. This study provides further evidence for stereoselectivity in neurochemical and behavioral actions of cathinone analogs. More importantly, stereoselective 4-methylcathinone effects on ICSS illustrate the potential for diametrically opposite effects of enantiomers in a preclinical behavioral assay of abuse potential. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
187. A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys.
- Author
-
Townsend, E. Andrew, Bremer, Paul T., Jacob, Nicholas T., Negus, S. Stevens, Janda, Kim D., and Banks, Matthew L.
- Subjects
- *
RHESUS monkeys , *OPIOID abuse , *VACCINE effectiveness , *OPIOIDS , *VACCINES - Abstract
Aim: Opioid-targeted vaccines are under consideration as candidate Opioid Use Disorder medications. We recently reported that a fentanyl-targeted vaccine produced a robust and long-lasting attenuation of fentanyl-vs-food choice in rats. In the current study, we evaluated an optimized fentanyl-targeted vaccine in rhesus monkeys to determine whether vaccine effectiveness to attenuate fentanyl choice translated to a species with greater phylogenetic similarity to humans.Methods: Adult male (2) and female (3) rhesus monkeys were trained to respond under a concurrent schedule of food (1 g pellets) and intravenous fentanyl (0, 0.032-1 μg/kg/injection) reinforcement during daily 2 h sessions. Fentanyl choice dose-effect functions were determined daily and 7-day buprenorphine treatments (0.0032-0.032 mg/kg/h IV; n = 4-5) were determined for comparison to vaccine effects. Subsequently, a fentanyl-CRM197 conjugate vaccine was administered at week 0, 3, 8, 15 over a 29-week experimental period during which fentanyl choice dose-effect functions continued to be determined daily.Results: Buprenorphine significantly decreased fentanyl choice and reciprocally increased food choice. Vaccination eliminated fentanyl choice and increased food choice in four-of-the-five monkeys. A transient and less robust vaccine effect was observed in the fifth monkey. Fentanyl-specific antibody concentrations peaked after the third vaccination to approximately 50 μg/mL while anti-fentanyl antibody affinity increased to a sustained low nanomolar level.Conclusion: These results translate fentanyl vaccine effectiveness from rats to rhesus monkeys to decrease fentanyl-vs-food choice, albeit with greater individual differences observed in monkeys. These results support the potential and further clinical evaluation of this fentanyl-targeted vaccine as a candidate Opioid Use Disorder medication. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
188. Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys.
- Author
-
Townsend, E. Andrew, Negus, S. Stevens, Poklis, Justin L., and Banks, Matthew L.
- Subjects
- *
RHESUS monkeys , *HEROIN , *OPIOID abuse , *SEROTONIN receptors , *INTRAVENOUS injections - Abstract
Background: The current opioid crisis has reinvigorated preclinical research in the evaluation of non-opioid candidate treatments for opioid use disorder (OUD). Emerging evidence suggests 5-HT2C receptor agonists may attenuate the abuse-related effects of opioids. This study evaluated effectiveness of 7-day treatment with the clinically available 5-HT2C agonist lorcaserin (Belviq®) on heroin-vs.-food choice in rhesus monkeys. Lorcaserin effects were compared to effects produced by 7-day saline substitution and by 7-day treatment with the opioid antagonist naltrexone.Methods: Adult male (1) and female (6) rhesus monkeys were trained to respond under a concurrent schedule of food delivery (1 g pellets, fixed-ratio 100 schedule) and intravenous heroin injections (0-0.032 mg/kg/injection, fixed-ratio 10 schedule) during daily 2 h sessions. Heroin choice dose-effect functions were determined daily before and following 7-day saline substitution or 7-day continuous treatment with naltrexone (0.0032-0.032 mg/kg/h, IV) or lorcaserin (0.032-0.32 mg/kg/h, IV).Results: Under baseline conditions, increasing heroin doses maintained a dose-dependent increase in heroin choice. Both saline substitution and 7-day naltrexone treatment significantly attenuated heroin choice and produced a reciprocal increase in food choice. Continuous lorcaserin (0.32 mg/kg/h) treatment significantly increased heroin choice.Conclusions: In contrast to saline substitution and naltrexone, lorcaserin treatment was ineffective to reduce heroin-vs.-food choice. These preclinical results do not support the therapeutic potential and continued evaluation of lorcaserin as a candidate OUD treatment. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
189. Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.
- Author
-
Schwienteck, Kathryn L., Blake, Steven, Bremer, Paul T., Poklis, Justin L., Townsend, E. Andrew, Negus, S. Stevens, and Banks, Matthew L.
- Subjects
- *
HEROIN , *SPRAGUE Dawley rats , *MORPHINE , *VACCINES , *VACCINE effectiveness , *ANALGESICS , *ANIMALS , *BACTERIAL vaccines , *DRUG administration , *DOSE-effect relationship in pharmacology , *FENTANYL , *IMMUNIZATION , *NALTREXONE , *NARCOTIC antagonists , *NARCOTICS , *RATS , *TETANUS , *PHARMACODYNAMICS - Abstract
Background: One emerging strategy to address the opioid crisis includes opioid-targeted immunopharmacotherapies. This study compared effectiveness of a heroin-tetanus toxoid (TT) conjugate vaccine to antagonize heroin, 6-acetylmorphine (6-AM), morphine, and fentanyl antinociception in rats.Methods: Adult male and female Sprague Dawley rats received three doses of active or control vaccine at weeks 0, 2, and 4. Vaccine pharmacological selectivity was assessed by comparing opioid dose-effect curves in 50 °C warm-water tail-withdrawal procedure before and after active or control heroin-TT vaccine. Route of heroin administration [subcutaneous (SC) vs. intravenous [IV)] was also examined as a determinant of vaccine effectiveness. Continuous naltrexone treatment (0.0032-0.032 mg/kg/h) effects on heroin, 6-AM, and morphine antinociceptive potency were also determined as a benchmark for minimal vaccine effectiveness.Results: The heroin-TT vaccine decreased potency of SC heroin (5-fold), IV heroin (3-fold), and IV 6-AM (3-fold) for several weeks without affecting IV morphine or SC and IV fentanyl potency. The control vaccine did not alter potency of any opioid. Naltrexone dose-dependently decreased antinociceptive potency of SC heroin, and treatment with 0.01 mg/kg/h naltrexone produced similar, approximate 8-fold decreases in potencies of SC and IV heroin, IV 6-AM, and IV morphine. The combination of naltrexone and active vaccine was more effective than naltrexone alone to antagonize SC heroin but not IV heroin.Conclusions: The heroin-TT vaccine formulation examined is less effective, but more selective, than chronic naltrexone to attenuate heroin antinociception in rats. Furthermore, these results provide an empirical framework for future preclinical opioid vaccine research to benchmark effectiveness against naltrexone. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
190. Effects of pharmacological and environmental manipulations on choice between fentanyl and shock avoidance/escape in male and female rats under mutually exclusive and non-exclusive choice conditions.
- Author
-
Marcus MM, Marsh SA, Arriaga M, Negus SS, and Banks ML
- Abstract
Substance use disorders are defined by persistent drug consumption despite adverse consequences. Accordingly, we developed two fentanyl-vs-shock avoidance/escape choice procedures in which male and female rats responded under a fixed-ratio (FR)1:FR1 concurrent schedule of shock avoidance/escape and IV fentanyl under either mutually exclusive or non-exclusive choice conditions. Initial experiments using a discrete-trial procedure determined behavioral allocation between mutually exclusive shock avoidance/escape and different fentanyl doses (0.32-18 μg/kg/infusion; Experiment 1). Shock intensity (0.1-0.7 mA) and shock avoidance/escape response requirement (FR1-16) were also manipulated (Experiment 2). Next, we used a free-operant procedure in which shock avoidance/escape and fentanyl were continuously available under non-exclusive conditions, and response-shock (R-S) interval (30-1000 s) was manipulated (Experiment 3). Finally, we tested the hypothesis that extended-access fentanyl self-administration would produce fentanyl dependence, establish fentanyl withdrawal as an endogenous negative reinforcer, and increase fentanyl choice in both procedures (Experiments 4 and 5). The shock avoidance/escape contingency decreased fentanyl self-administration, and rats consistently chose shock avoidance/escape over fentanyl in both choice conditions. Decreasing shock intensity or increasing shock avoidance/escape response requirement failed to increase fentanyl choice, suggesting that fentanyl and shock avoidance/escape are independent economic commodities. Increasing the R-S interval increased fentanyl choice but failed to increase shock delivery. Extended fentanyl access engendered high fentanyl intake and opioid withdrawal signs but failed to increase fentanyl choice under either choice condition. These results suggest that neither positive fentanyl reinforcement nor negative reinforcement by fentanyl withdrawal is sufficient to reduce shock avoidance/escape-maintained responding and increase foot shock as an adverse consequence., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
191. Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments.
- Author
-
St Onge CM, Pagare PP, Zheng Y, Arriaga M, Stevens DL, Mendez RE, Poklis JL, Halquist MS, Selley DE, Dewey WL, Banks ML, and Zhang Y
- Subjects
- Structure-Activity Relationship, Animals, Mice, Male, Humans, Receptors, Opioid, kappa agonists, Receptors, Opioid, kappa metabolism, Pain Management methods, Pain drug therapy, Analgesics pharmacology, Analgesics chemistry, Analgesics chemical synthesis, Analgesics therapeutic use, Spiro Compounds chemistry, Spiro Compounds pharmacology, Spiro Compounds chemical synthesis, Morphinans pharmacology, Morphinans chemistry, Morphinans chemical synthesis, Morphinans therapeutic use
- Abstract
Despite the availability of numerous pain medications, the current array of Food and Drug Administration-approved options falls short in adequately addressing pain states for numerous patients and consequently worsens the opioid crisis. Thus, it is imperative for basic research to develop novel and nonaddictive pain medications. Toward addressing this clinical goal, nalfurafine (NLF) was chosen as a lead and its structure-activity relationship (SAR) systematically studied through design, syntheses, and in vivo characterization of 24 analogues. Two analogues, 21 and 23 , showed longer durations of action than NLF in a warm-water tail immersion assay, produced in vivo effects primarily mediated by KOR and DOR, penetrated the blood-brain barrier, and did not function as reinforcers. Additionally, 21 produced fewer sedative effects than NLF. Taken together, these results aid the understanding of NLF SAR and provide insights for future endeavors in developing novel nonaddictive therapeutics to treat pain.
- Published
- 2024
- Full Text
- View/download PDF
192. The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder.
- Author
-
Banks ML and Sprague JE
- Subjects
- Humans, Dopamine, Receptors, Dopamine D3 genetics, Dopamine Antagonists, Dopamine Agonists, Analgesics, Opioid, Receptors, Dopamine, Opioid-Related Disorders genetics
- Abstract
Here, we present recent studies suggesting that specific DRD3 single nucleotide polymorphisms (SNPs, e.g. rs324029 and rs2654754) might serve as prognostic biomarkers for opioid use disorder (OUD). Additionally, preclinical studies with novel dopamine 3 receptor (D3R) partial agonists and antagonists have been evaluated as candidate OUD therapeutics and have shown a reduced risk of cardiovascular toxicity compared with the original D3R antagonist. From these findings, we argue that DRD3 SNPs could serve as a diagnostic tool for assessing OUD risk and that more research is warranted examining the D3R as a safe and effective therapeutic target for treating OUD., (© 2024 The Authors. Addiction Biology published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.)
- Published
- 2024
- Full Text
- View/download PDF
193. Effects of naltrexone on amphetamine choice in rhesus monkeys and rats.
- Author
-
Robinson HL, Moerke MJ, Banks ML, and Negus SS
- Subjects
- Male, Female, Rats, Animals, Amphetamine pharmacology, Naltrexone pharmacology, Naltrexone therapeutic use, Macaca mulatta, Narcotic Antagonists pharmacology, Narcotic Antagonists therapeutic use, Choice Behavior, Dose-Response Relationship, Drug, Self Administration, Cocaine, Substance-Related Disorders drug therapy
- Abstract
Clinical amphetamine use is constrained by high abuse potential, and amphetamine use disorder is a persistent clinical problem with no approved medications for its treatment. The opioid antagonist naltrexone has been reported to reduce some abuse-related effects of amphetamine. This study used an amphetamine-versus-food choice procedure in rhesus monkeys and rats to test the hypothesis that naltrexone might serve as either (a) a maintenance medication for amphetamine use disorder treatment or (b) an "abuse-deterrent" adjunct to clinical amphetamine formulations. Male rhesus monkeys and male and female rats were trained to choose between increasing unit doses of intravenous amphetamine and an alternative food reinforcer during daily behavioral sessions. Experiment 1 evaluated effectiveness of continuous naltrexone maintenance to reduce amphetamine-versus-food choice in both monkeys and rats. Experiment 2 combined naltrexone with amphetamine in fixed-proportion amphetamine + naltrexone mixtures to evaluate the effectiveness of naltrexone in both species to reduce mixture choice relative to amphetamine-alone choice. Amphetamine maintained a dose-dependent increase in amphetamine choice in both monkeys and rats. Naltrexone maintenance did not significantly decrease amphetamine choice in either species. Addition of naltrexone to amphetamine reduced amphetamine choices per session in monkeys, but behavior was not reallocated to food choice, and in rats, the addition of naltrexone only decreased food choice without significantly affecting amphetamine choice. These results argue against the use of naltrexone as either (a) a maintenance medication for treatment of amphetamine use disorder or (b) an "abuse-deterrent" adjunct to amphetamine for clinical applications. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- Published
- 2023
- Full Text
- View/download PDF
194. Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.
- Author
-
Woodlief K, Allen MI, Cornelissen JC, Banks ML, Newman AH, and Nader MA
- Subjects
- Animals, Female, Male, Analgesics, Opioid pharmacology, Dopamine Agonists pharmacology, Dopamine Antagonists pharmacology, Dose-Response Relationship, Drug, Naltrexone pharmacology, Self Administration, Macaca fascicularis, Opioid-Related Disorders, Oxycodone administration & dosage, Receptors, Dopamine D3 drug effects
- Abstract
Recent studies suggest that dopamine D3 receptors (D3R) may be a therapeutic target for opioid use disorders (OUD). This study examined the effects of the D3R partial agonist (±)VK4-40 and the D3R-selective antagonist (±)VK4-116, compared to the mu-opioid receptor antagonist naltrexone (NTX), in nonhuman primate models of OUD and antinociception. Adult male and female (N = 4/sex) cynomolgus monkeys were trained to self-administer oxycodone (0.003-0.1 mg/kg/injection) first under a fixed-ratio (FR) and then a progressive-ratio (PR) schedule of reinforcement during daily 1- and 4-hr sessions, respectively. Under the FR schedule, intravenous NTX (0.01-0.1 mg/kg), (±)VK4-116 (1.0-10 mg/kg), and (±)VK4-40 (1.0-10 mg/kg) were studied in combination with the peak oxycodone dose and a dose on the descending limb of the dose-effect curve; NTX and (±)VK4-40 were also studied at the peak of the PR dose-response curve (N = 4). Following saline extinction, each compound was examined on oxycodone-induced reinstatement. Finally, these compounds were assessed in adult male rhesus monkeys (N = 3) in a warm-water (38 °C, 50 °C, 54 °C) tail withdrawal assay. NTX decreased responding on the peak of the FR oxycodone dose-response curve, but increased responding on the descending limb. (±)VK4-40, but not (±)VK4-116, significantly decreased peak oxycodone self-administration; (±)VK4-40 did not increase responding on the descending limb. NTX and (±)VK4-40, but not (±)VK4-116, attenuated oxycodone-induced reinstatement. Under PR responding, NTX and (±)VK4-40 decreased breakpoints. Oxycodone-induced antinociception was attenuated by NTX, but not by (±)VK4-40 or (±)VK4-116. Together, these results suggest that further research evaluating the effects of (±)VK4-40 as a novel pharmacotherapy for OUD is warranted., (© 2023. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.)
- Published
- 2023
- Full Text
- View/download PDF
195. Effects of environmental and pharmacological manipulations on cocaine-vs-negative reinforcer choice in male and female rats.
- Author
-
Marcus MM and Banks ML
- Subjects
- Humans, Rats, Male, Female, Animals, Reinforcement, Psychology, Punishment, Diazepam, Self Administration, Dose-Response Relationship, Drug, Reinforcement Schedule, Cocaine, Cocaine-Related Disorders
- Abstract
Rationale: The adverse consequences of human addictive drug use could be the result of either addictive drug consumption resulting in punishment (e.g., incarceration) or failure to engage in negative-reinforced behaviors that might compete with drug-maintained behaviors (e.g., contingency management strategies that reset payment amounts for drug free urines)., Objective: The goal of the present study was to establish a discrete-trial cocaine-vs-negative reinforcer (S
NR ) choice procedure where rats were presented with a simplified model of this conflict: choose negative reinforcement (i.e., escape or avoid foot shock) or choose an intravenous (IV) cocaine infusion followed by an inescapable shock., Methods: Responding was maintained in male and female rats by IV cocaine infusions (0.32-1.8 mg/kg/inf) and a SNR (0.1-0.7 mA shock) under a discrete-trial concurrent "choice" schedule during daily sessions. Following parametric reinforcer magnitude and response requirement experiments, the effects of 12 h extended access cocaine self-administration and acute diazepam (0.32-10 mg/kg, IP) pretreatment were determined on cocaine-vs-SNR choice., Results: Negative reinforcement was chosen over all cocaine doses. Lowering shock magnitude or increasing SNR response requirement failed to promote behavioral reallocation towards cocaine. Extended access cocaine self-administration sessions resulted in high daily cocaine intakes but failed to significantly increase cocaine choice in all (19) but one rat. Acute diazepam pretreatment also did not alter choice behavior up to doses that produced behavioral depression., Conclusions: These results suggest that SNR s may be a source of reinforcement that effectively compete with and mitigate maladaptive addictive drug-maintained behaviors in the general population., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
196. A concurrently available negative reinforcer robustly decreases cocaine self-administration in male and female rats.
- Author
-
Marcus MM and Banks ML
- Abstract
Continued drug-taking despite adverse consequences is hypothesized to be an insidious behavioral hallmark of drug addiction. Although most preclinical research has focused on drug self-administration in the presence of positive punishment, another source of potential adverse consequences is behavioral allocation away from negative reinforcers (i.e., escape/avoid electric shock) and towards drug reinforcers. The goals of the present study were to establish a discrete-trial cocaine-vs-negative reinforcer choice procedure in male and female rats and determine sensitivity of choice behavior to environmental and pharmacological manipulations. Rats could make up to nine discrete choices between an intravenous cocaine infusion (0.32 - 1.8 mg/kg/inf) under a fixed-ratio (FR) 3 schedule and a negative reinforcer (escape or avoidance of electric shock, 0.1 - 0.7 mA) under an FR1 schedule. The negative reinforcer was consistently chosen over all cocaine doses. Lowering shock magnitude decreased negative reinforcer trials, increased omitted trials, and failed to promote behavioral reallocation towards cocaine. Increasing the negative reinforcement response requirement between sessions only increased omitted trials. Introduction of 12-hr extended access cocaine self-administration sessions across two weeks resulted in high daily cocaine intakes but failed to significantly increase cocaine choice. Acute diazepam pretreatment also did not impact choice behavior up to doses that produced behavioral depression. Overall, the lack of behavioral allocation between cocaine infusions and a negative reinforcer suggests these two reinforcers may be economic independents. Additionally, the failure of extended cocaine access to increase cocaine choice highlights the importance of alternative reinforcers and environmental context in preclinical models of drug addiction.
- Published
- 2023
- Full Text
- View/download PDF
197. Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.
- Author
-
Li M, Stevens DL, Arriaga M, Townsend EA, Mendez RE, Blajkevch NA, Selley DE, Banks ML, Negus SS, Dewey WL, and Zhang Y
- Subjects
- Humans, Receptors, Opioid, kappa agonists, Analgesics pharmacology, Structure-Activity Relationship, Receptors, Opioid, mu agonists, Analgesics, Opioid chemistry, Morphinans pharmacology
- Abstract
Discovery of analgesics void of abuse liability is critical to battle the opioid crisis in the United States. Among many strategies to achieve this goal, targeting more than one opioid receptor seems promising to minimize this unwanted side effect while achieving a reasonable therapeutic profile. In the process of understanding the structure-activity relationship of nalfurafine, we identified a potential analgesic agent, NMF, as a dual kappa opioid receptor/delta opioid receptor agonist with minimum abuse liability. Further characterizations, including primary in vitro ADMET studies (hERG toxicity, plasma protein binding, permeability, and hepatic metabolism), and in vivo pharmacodynamic and toxicity profiling (time course, abuse liability, tolerance, withdrawal, respiratory depression, body weight, and locomotor activity) further confirmed NMF as a promising drug candidate for future development.
- Published
- 2022
- Full Text
- View/download PDF
198. Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.
- Author
-
Pagare PP, Obeng S, Huang B, Marcus MM, Nicholson KL, Townsend AE, Banks ML, and Zhang Y
- Abstract
Mu opioid receptor (MOR) selective antagonists and partial agonists have clinical utility for the treatment of opioid use disorders (OUDs). However, the development of many has suffered due to their poor pharmacokinetic properties and/or rapid metabolism. Our recent efforts to identify MOR modulators have provided 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ), a low-efficacy partial agonist, that showed sub-nanomolar binding affinity to the MOR ( K
i 0.6 nM) with selectivity over the delta opioid receptor (δ/μ 241) and the kappa opioid receptor (κ/μ 48). Its potent inhibition of the analgesic effect of morphine (AD50 0.46 mg/kg) and precipitation of significantly less withdrawal symptoms even at 100-fold greater dose than naloxone represents a promising molecule for further development as a novel OUD therapeutic agent. Therefore, further in vitro and in vivo characterization of its pharmacokinetics and pharmacodynamics properties was conducted to fully understand its pharmaceutical profile. NAQ showed favorable in vitro ADMET properties and no off-target binding to several classes of GPCRs, enzymes, and ion channels. Following intravenous administration, 1 mg/kg dose of NAQ showed a similar in vivo pharmacokinetic profile to naloxone; however, orally administered 10 mg/kg NAQ demonstrated significantly improved oral bioavailability over both naloxone and naltrexone. Abuse liability assessment of NAQ in rats demonstrated that NAQ functioned as a less potent reinforcer than heroin. Chronic 5 day NAQ pretreatment decreased heroin self-administration in a heroin-vs-food choice procedure similar to the clinically used MOR partial agonist buprenorphine. Taken together, these studies provide evidence supporting NAQ as a promising lead to develop novel OUD therapeutics., Competing Interests: The authors declare no competing financial interest., (© 2022 American Chemical Society.)- Published
- 2022
- Full Text
- View/download PDF
199. Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.
- Author
-
Townsend EA, Blough BE, Epstein DH, Negus SS, Shaham Y, and Banks ML
- Subjects
- Analgesics, Opioid, Animals, Fentanyl pharmacology, Male, Methadone pharmacology, Methadone therapeutic use, Narcotics, Rats, Receptors, Opioid, Spiro Compounds, Thiophenes, Buprenorphine pharmacology, Opioid-Related Disorders drug therapy, Substance Withdrawal Syndrome drug therapy
- Abstract
The high efficacy mu-opioid receptor (MOR) agonist methadone is an effective opioid use disorder (OUD) medication used exclusively in opioid-dependent patients. However, methadone has undesirable effects that limit its clinical efficacy. Intermediate efficacy MOR agonists may treat OUD with fewer undesirable effects. We compared the effects of methadone with the intermediate efficacy MOR agonist TRV130 (oliceridine) on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats. Male rats (n = 20) were trained under a fentanyl-vs.-food choice procedure. Rats were then provided extended fentanyl (3.2 µg/kg/infusion) access (6 p.m.-6 a.m.) for 10 days to produce opioid dependence/withdrawal. Rats were treated with vehicle (n = 7), TRV130 (3.2 mg/kg; n = 8), or methadone (3.2 mg/kg; n = 5) three times per day after each extended-access session (8:30 a.m., 11 a.m., 1:30 p.m.). Withdrawal sign scoring (1:55 p.m.) and choice tests (2-4 p.m.) were conducted daily. Vehicle, TRV130, and methadone effects on fentanyl choice were redetermined in post-opioid-dependent rats. Vehicle-, TRV130-, and methadone-treated rats had similar fentanyl intakes during extended access. Vehicle-treated rats exhibited increased withdrawal signs and decreased bodyweights. Both methadone and TRV130 decreased these withdrawal signs. TRV130 was less effective than methadone to decrease fentanyl choice and increase food choice in opioid-dependent rats. Neither methadone nor TRV130 decreased fentanyl choice in post-opioid-dependent rats. Results suggest that higher MOR activation is required to reduce fentanyl choice than withdrawal signs in fentanyl-dependent rats. Additionally, given that TRV130 did not precipitate withdrawal in opioid-dependent rats, intermediate efficacy MOR agonists like TRV130 may facilitate the transition of patients with OUD from methadone to lower efficacy treatments like buprenorphine., (© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.)
- Published
- 2022
- Full Text
- View/download PDF
200. Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice.
- Author
-
Santos EJ, Banks ML, and Negus SS
- Subjects
- Analgesics, Opioid pharmacology, Animals, CHO Cells, Cricetinae, Cricetulus, Dose-Response Relationship, Drug, Female, Fentanyl pharmacology, Ligands, Male, Mice, Rats, Naltrexone pharmacology, Receptors, Opioid, mu metabolism
- Abstract
Mu opioid receptor (MOR) agonists produce locomotor hyperactivity in mice as one sign of opioid-induced motor disruption. The goal of this study was to evaluate the degree of MOR efficacy required to produce this hyperactivity. Full dose-effect curves were determined for locomotor activation produced in male and female Institute of Cancer Research (ICR) mice by (1) eight different single-molecule opioids with high to low MOR efficacy and (2) a series of fixed-proportion fentanyl/naltrexone mixtures with high to low fentanyl proportions. Data from the mixtures were used to quantify the efficacy requirement for MOR agonist-induced hyperactivity relative to efficacy requirements determined previously for other MOR agonist effects. Specifically, efficacy requirement was quantified as the EP50 value, which is the "Effective Proportion" of fentanyl in a fentanyl/naltrexone mixture that produces a maximal effect equal to 50% of the maximal effect of fentanyl alone. Maximal hyperactivity produced by each drug and mixture in the present study correlated with previously published data for maximal stimulation of GTPɣS binding in MOR-expressing Chinese hamster ovary cells as an in vitro measure of relative efficacy. Additionally, the EP
50 value for hyperactivity induced by fentanyl/naltrexone mixtures indicated that opioid-induced hyperactivity in mice has a relatively high efficacy requirement in comparison with some other MOR agonist effects, and in particular is higher than the efficacy requirement for thermal antinociception in mice or fentanyl discrimination in rats. Taken together, these data show that MOR agonist-induced hyperactivity in mice is efficacy dependent and requires relatively high levels of MOR agonist efficacy for its full expression. SIGNIFICANCE STATEMENT: Mu opioid receptor (MOR) agonist-induced hyperlocomotion in mice is dependent on the MOR efficacy of the agonist and requires a relatively high degree of efficacy for its full expression., (Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.)- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.